Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Tirzepatide and cardiovascular outcomes
BMJ (Clinical research ed.), 2026;394:e100366
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
BMJ (Clinical research ed.), 2026;394:e100011
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity
Pharmacological research, 2026;:108365
Cup-to-disc ratio in GLP-1 RA Associated Non-Arteritic Anterior Ischemic Optic Neuropathy
Ophthalmology, 2026
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study)
Metabolism open, 2026;31:100489
Quality and reliability of semaglutide-related health information on Chinese short-video platforms: a cross-sectional study of Bilibili and TikTok
Frontiers in public health, 2026;14:1826485
Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence
Medicina (Kaunas, Lithuania), 2026;62(8)
In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk
Annals of internal medicine, 2026
AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice
Proceedings of the National Academy of Sciences of the United States of America, 2026;123(32):e2614476123
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues
Expert review of endocrinology & metabolism, 2026;:1-12
GLP-1 Receptor Agonist Therapy for Obesity Under Japan’s Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain
Diabetes, obesity & metabolism, 2026
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026
Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report
JAAD case reports, 2026;76:41-43
Acute pancreatitis following semaglutide therapy: a case report
Annals of medicine and surgery (2012), 2026;88(9):6164-6166
Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital
The Journal of the Association of Physicians of India;74(6):74-77
Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study
Pediatric obesity;21(8):e70139
Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India
The Journal of the Association of Physicians of India;74(6):94-96
GLP-1 receptor agonists in hip, knee and shoulder arthroplasty: Implications for obesity, osteoarthritis, metabolic optimisation and complications
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2026
Development and validation of a sensitive HPLC-MS/MS method for the analysis of semaglutide in human plasma
Bioanalysis, 2026;:1-10
Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy
Childhood obesity (Print), 2026;:21532176261475103